Market Cap | 92.45M | P/E | - | EPS this Y | 21.40% | Ern Qtrly Grth | - |
Income | -105.54M | Forward P/E | -1.59 | EPS next Y | 32.00% | 50D Avg Chg | -7.00% |
Sales | 165.9M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -56.00% |
Dividend | N/A | Price/Book | 1.28 | EPS next 5Y | - | 52W High Chg | -78.00% |
Recommedations | 1.70 | Quick Ratio | 0.23 | Shares Outstanding | 83.29M | 52W Low Chg | 13.00% |
Insider Own | 31.05% | ROA | -3.27% | Shares Float | 32.31M | Beta | 1.96 |
Inst Own | 35.23% | ROE | -102.75% | Shares Shorted/Prior | 412.18K/129.95K | Price | 1.11 |
Gross Margin | 54.66% | Profit Margin | -60.32% | Avg. Volume | 600,892 | Target Price | 5.75 |
Oper. Margin | -8.47% | Earnings Date | Mar 28 | Volume | 296,322 | Change | -1.77% |
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.